Published 1 day ago • loading... • Updated 1 day ago

SLNO Investigation: Investors Encouraged to Contact Kirby McInerney LLP

Kirby McInerney LLP in New York announced on January 16, 2026, an investigation into Soleno Therapeutics, Inc., citing recent disclosures and inviting affected investors to contact Lauren Molinaro, Esq.
On Friday, Scorpion Capital's short‑seller claims Vykat XR was overpriced and unsafe, and the company's CEO acknowledged the report disrupted the launch, reducing start forms and increasing discontinuations.
Shares dropped from $77.36 to $71.64 after the August report, reflecting a 7.41% decline, and Soleno disclosed an 8% Vykat XR discontinuation rate at Q3 fiscal 2025 end.
Kirby McInerney is asking affected investors to contact Lauren Molinaro, Esq. to discuss potential claims at no cost, and shareholders must file lead plaintiff motions by January 16, 2026.
The complaint alleges that investors suffered damages when details reached the market, and participation and recovery rules note investors may be eligible with contingency‑fee representation.

Insights by Ground AI

41 Articles

SLNO Investigation: Investors Encouraged to Contact Kirby McInerney LLP - Soleno Therapeutics (NASDAQ:SLNO)

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ:SLNO) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 15, 2025, Scorpion Capita…

1 day ago·New York, United States

Read Full Article